Clostridium beijerinckii as Next Generation Probiotics
Background C. beijerinckii for Cancer Products FAQs Resources
Introduction of Clostridium beijerinckii
Both wild-type and genetically engineered Clostridium beijerinckii can be used to achieve tumor-specific drug activation, which is an innovative approach for cancer therapy. Based on our advanced technology platforms and extensive experience, Creative Biolabs has won a good reputation for accomplishing challenging C. beijerinckii based drug discovery projects for our customers all over the world.
Introduction of Clostridium beijerinckii
Clostridium beijerinckii is a gram-positive, rod-shaped, motile bacterium of the genus Clostridium. It exhibits peritrichous flagella. C. beijerinckii species are ubiquitous and routinely isolated from soil samples. It produces oval to subterminal spores, and the morphology of the cell changes over the growth cycle of the organism. Obligate anaerobes C. beijerinckii employs hypoxic germination. C. beijerinckii is the industrially valuable nonpathogenic species of the genus Clostridium.
Clostridium beijerinckii for Cancer Therapy
Despite substantial investment in prevention, treatment, and aftercare, cancer remains a leading cause of death worldwide. A potential solution is the use of endospore-forming Clostridium species such as C beijerinckii, either on their own or as a tumor delivery vehicle for anti-cancer drugs. Clostridium species of anaerobic bacteria thrive and consume oxygen-poor cancerous tissue, whereas dying when they come in contact with the tumor's oxygenated sides. Clostridial spores can home in on these niche environments because of their own unique metabolic need, which enables them to utilize the tumor micro milieu and respective tissues for their proliferation. Both wild-type and genetically modified C. beijerinckii have been demonstrated to colonize and destroy solid tumors specifically.
Fig.1 Treatment of tumors with Clostridium.1
C. beijerinckii is amenable to genetic manipulation and has successfully been modified to express several enzymes, which activate different prodrugs. C beijerinckii can be successfully engineered to express genes encoding specific bacterial enzymes (cytosine deaminase, nitroreductase), producing more promising antitumor effects. The CD gene is cloned into a Clostridial expression vector and transformed into C. beijerinckii. Corresponding to CD, similar gene therapy approaches are performed using the E. coli NTR gene in C. beijerinckii. Although CDase or NTR are produced intracellularly, the amounts present in the culture supernatants are enough to kill tumor cells in vitro in the presence of the appropriate prodrug. Expression of the NTR gene by Clostridium in vitro enhanced tumor cell death, and NTR activity is detected in tumors following intravenous administration to mice bearing tumors. The antitumor effects of bacterial treatment can be increased by the application of these engineered C. beijerinckii.
Certain species of obligate anaerobic bacteria, such as C. beijerinckii, have been shown to provide tumor specificity for therapy. Based on our deep understanding of C. beijerinckii, Creative Biolabs can provide C. beijerinckii based drug discovery for our customers all over the world. If you want to know more information, please do not hesitate to contact us.
Related Products
FAQs
What are the key characteristics of Clostridium beijerinckii that make it suitable for use as a next generation probiotic?
Clostridium beijerinckii is a gram-positive, rod-shaped, and motile bacterium. It is nonpathogenic and capable of forming spores, making it resilient in various environments. This bacterium's ability to thrive in oxygen-poor conditions, such as those found in tumorous tissues, adds to its potential in targeted therapeutic applications.
What are the mechanisms by which Clostridium beijerinckii interacts with the human immune system?
Clostridium beijerinckii, have been shown to play a role in maintaining gut health and immune tolerance. These bacteria can interact with the intestinal immune system to promote regulatory T cell functions and produce short-chain fatty acids like butyrate, which have anti-inflammatory properties.
What unique capabilities does Creative Biolabs offer for the development of Clostridium beijerinckii-based therapeutics?
Our platform specializes in the advanced genetic engineering of Clostridium beijerinckii, enabling the development of tailored strains that can effectively target specific diseases. We utilize cutting-edge sequencing and bioinformatics tools to enhance the bacterium's therapeutic efficacy and safety, ensuring high-quality candidate probiotics for clinical applications.
What are the advantages of using Clostridium beijerinckii in live biotherapeutic products over other probiotic strains?
Clostridium beijerinckii is particularly effective in targeting hypoxic environments like solid tumors due to its anaerobic growth capabilities and specific metabolic pathways. Its genetic modifiability makes it a valuable tool in precision medicine, especially for cancer therapies requiring targeted delivery.
How does Creative Biolabs support the scale-up production of Clostridium beijerinckii for clinical trials?
Creative Biolabs offers comprehensive process development, optimization, and cGMP manufacturing services. This ensures that once a Clostridium beijerinckii strain is developed, it can be scaled up efficiently and produced under stringent quality controls suitable for both clinical trials and commercial purposes.
Resources
Reference
-
Paton, A.W.; et al. Bioengineered microbes in disease therapy. Trends in molecular medicine. 2012. 18(7), pp.417-425.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
